Cancer-Attributable Medical Costs for Colorectal Cancer Patients by Phases of Care: What Is the Effect of a Prior Cancer History?. Issue 55 (15th May 2020)

• Record Type: Journal Article
• Authors: Mariotto, Angela B; Warren, Joan L; Zeruto, Chris; Coughlan, Diarmuid; Barrett, Michael J; Zhao, Lirong; Yabroff, K Robin
• Is Part Of: Journal of the National Cancer Institute. Issue 55(2020)
• Page Start: 22
• Page End: 30
• Publication Date: 2020-05-15
• Subjects: Cancer -- Periodicals; Cancer -- Congresses; 616.994
• DOI: 10.1093/jncimonographs/lgz032
• Languages: English
• ISSNs: 1052-6773

Abstract

Abstract: Medical care costing studies have excluded patients with a prior cancer history. This study aims to update methods for estimating medical care costs attributable to cancer and to evaluate the effect of a prior history of cancer on costs for colorectal cancer (CRC) patients. We used Surveillance, Epidemiology, and End Results (SEER)-Medicare data and matched cancer patients to controls without cancer to estimate cancer-attributable costs by phases of care using Medicare 2007–2013 claims. CRC annualized average cancer-attributable costs were $56.0 K, $5.3 K, $92.5 K, and $24.3 K in the initial, continuing, and end-of-life cancer and noncancer death phases, respectively, in 2014 dollars. Costs were higher for patients diagnosed with more advanced stage, younger ages, and nonwhite races. Costs for patients with prior cancers were consistently higher than patients without prior cancers, especially in the continuing (4.9 K vs 7.2 K) and end-of-life noncancer death (22.7 K vs 30.0 K). Our CRC costs improve previous estimates by using more recent data and updated methods.